About The Study: In this analysis of the top 1,000 generics in Colorado's all-payer claims database in 2019, researchers identified 45 high-cost products that had lower-cost therapeutic alternatives of same clinical value. Overall, high-cost generics were 15.6 times more expensive than their therapeutic alternatives (median values). If the lower-cost alternatives had been used, total spending would have been reduced by 88%. Substitution of high-cost generics may provide a simple pathway to offer the same therapeutic benefit at lower cost to patients and insurers.
Authors: Mariana P. Socal, M.D., Ph.D., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.39868)
